Published in Med Times on September 01, 1967
A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature (2001) 42.18
THE EFFECT IN PATIENTS OF STREPTOCOCCAL FIBRINOLYSIN (STREPTOKINASE) AND STREPTOCOCCAL DESOXYRIBONUCLEASE ON FIBRINOUS, PURULENT, AND SANGUINOUS PLEURAL EXUDATIONS. J Clin Invest (1949) 8.50
Thrombolytic therapy: current status (1). N Engl J Med (1988) 5.44
THE VITAMIN C REQUIREMENT OF MAN. ESTIMATED AFTER PROLONGED STUDIES OF THE PLASMA CONCENTRATION AND DAILY EXCRETION OF VITAMIN C IN 3 ADULTS ON CONTROLLED DIETS. J Clin Invest (1939) 2.43
Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest (1969) 1.52
Coronary thrombosis in myocardial infarction. Report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. Am J Cardiol (1974) 1.51
Thrombolytic therapy: current status (2). N Engl J Med (1988) 1.49
The kallikreinogen-kallikrein enzyme system of human plasma. Assay of components and observations in disease states. Ann Intern Med (1969) 1.45
Detection of serum fibrinogen and fibrin degradation products. Comparison of six technics using purified products and application in clinical studies. Am J Med (1971) 1.41
Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. J Clin Invest (1969) 1.34
Current status of antithrombotic therapy in cardiovascular disease. Prog Cardiovasc Dis (1977) 1.31
The preparation and properties of human fibrinogen of relatively high solubility. Biochemistry (1966) 1.31
THE MECHANISM OF THE EXCRETION OF VITAMIN C BY THE HUMAN KIDNEY AT LOW AND NORMAL PLASMA LEVELS OF ASCORBIC ACID. J Clin Invest (1940) 1.30
Comparative activity of thrombin on substituted arginine and lysine esters. Am J Physiol (1965) 1.28
Fibrinolysis. Annu Rev Med (1968) 1.20
Human fibrinogen of relatively high solubility. Comparative biophysical, biochemical, and biological studies with fibrinogen of lower solubility. Biochemistry (1967) 1.17
Thrombolytic therapy: reocclusion rates with adjunctive aspirin and its relation to heparin therapy. J Am Coll Cardiol (1992) 1.07
Chronic intravascular coagulation syndrome. N Engl J Med (1968) 1.06
Coronary thrombolysis by intravenous streptokinase in acute myocardial infarction: acute and follow-up studies. Am J Cardiol (1984) 1.03
Nightmares and trauma: a comparison of nightmares after combat with lifelong nightmares in veterans. Am J Psychiatry (1984) 0.99
Editorial: Lwo=dose heparin prophylaxis for postoperative venous thromboembolism. N Engl J Med (1975) 0.98
Coronary thrombolysis for evolving myocardial infarction. Drugs (1984) 0.96
Effect of urokinase antiserum on plasminogen activators: demonstration of immunologic dissimilarity between plasma plasminogen activator and urokinase. J Clin Invest (1968) 0.95
Tissue plasminogen activator (t-PA). Will it fulfill its promise? N Engl J Med (1985) 0.92
High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: description of effects in the circulation. Am J Cardiol (1986) 0.88
Sulfinpyrazone: a review of its pharmacological properties and therapeutic use. Drugs (1980) 0.88
The urokinase-pulmonary embolism trial. Circulation (1969) 0.88
High-dose, brief intravenous streptokinase early in acute myocardial infarction. Am Heart J (1982) 0.87
Immunoelectrophoretic characterization of plasma fibrinogen derivatives in patients with pathological plasma proteolysis. J Lab Clin Med (1967) 0.87
Appraisal of various thrombolytic agents in the treatment of acute myocardial infarction. Am J Med (1987) 0.87
[Activity of plasmin and streptokinase-activator on substituted arginine and lysine esters]. Thromb Diath Haemorrh (1966) 0.87
Controlled trial of low-dose heparin and sulfinpyrazone to prevent venous thromboembolism after operation on the hip. J Bone Joint Surg Am (1978) 0.86
Observations on the spontaneous arginine and lysine esterase activity of human plasma, and their relation to Hageman factor. Thromb Diath Haemorrh Suppl (1966) 0.86
Isolation and characterization of the clottable low molecular weight fibrinogen derived by limited plasmin hydrolysis of human fraction I-4. Biochemistry (1969) 0.86
Clinical trials with antithrombotic and thrombolytic agents. Principles and pitfalls. Thromb Diath Haemorrh (1973) 0.86
Clinical aspects of antiplatelet therapy. Semin Hematol (1985) 0.86
Clinical management of the thrombosed vessel: an overview. Angiology (1982) 0.85
Recombinant tissue plasminogen activator (rt-PA): is it the thrombolytic agent of choice for an evolving acute myocardial infarction? Am J Cardiol (1987) 0.84
NCBI genetic resources supporting immunogenetic research. Rev Immunogenet (2000) 0.84
The purification of fibrinogen degradation products by pevikon block electrophoresis. Thromb Diath Haemorrh (1969) 0.84
In vivo transformation between fibrinogens of varying ethanol solubilities: a pathway of fibrinogen catabolism. J Lab Clin Med (1969) 0.83
The urokinase-streptokinase pulmonary embolism trial (phase II) results. Circulation (1974) 0.83
Thrombosis prevention. N Engl J Med (1971) 0.82
Fibrinolysis and afibrinogenemia. Anesthesiology (1966) 0.81
Pharmacology and pharmacokinetics of platelet-active drugs under current clinical investigation. Adv Prostaglandin Thromboxane Leukot Res (1982) 0.80
Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. Am J Cardiol (1986) 0.80
Intra-arterial thrombolytic therapy in peripheral vascular disease. Surg Gynecol Obstet (1987) 0.80
Reaction of plasmic degradation products of fibrinogen in the radioimmunoassay of human fibrinopeptide A. Blood (1975) 0.79
Streptokinase therapy for thromboembolic occlusive vascular disease. Ann Intern Med (1971) 0.79
Frustrations with clinical trials. Eur J Clin Pharmacol (1980) 0.79
Personal reflections on the development of thrombolytic therapy and its application to acute coronary thrombosis. Am Heart J (1981) 0.79
Fibrinolytic mechanisms in tissue injury. Gastroenterology (1966) 0.79
The phase II urokinase-streptokinase pulmonary embolism trial: a national cooperative study. Thromb Diath Haemorrh (1975) 0.79
The proteolysis of fibrinogen by plasmin: the identification of thrombin-clottable fibrinogen derivatives which polymerize abnormally. J Lab Clin Med (1966) 0.78
The status of information about the use of blood, blood substitutes, and adjuvant solutions for extracorporeal circulation. Transfusion (1967) 0.78
The problem of thromboembolic disease. Semin Nucl Med (1977) 0.78
The current and future use of thrombolytic therapy. Annu Rev Pharmacol Toxicol (1985) 0.77
The anturane reinfarction trial. Circulation (1980) 0.77
A fibrinolytic defect in the respiratory distress syndrome. N Engl J Med (1990) 0.75
Thrombo-embolism. Proc Inst Med Chic (1977) 0.75
Current developments in thrombolytic therapy. Thromb Diath Haemorrh Suppl (1973) 0.75
William Smith Tillett. 1892-1974. Trans Assoc Am Physicians (1975) 0.75
The Anturane reinfarction trial. Thromb Haemost (1979) 0.75
Platelet coagulant activities and venous thrombosis after hip surgery. Trans Assoc Am Physicians (1974) 0.75
Diabetes mellitus: a frequent factor in liability claims. N J Med (1994) 0.75
Report of the Subcommittee on Fibrinolysis and Thrombolysis. Thromb Diath Haemorrh Suppl (1967) 0.75
Thomas Morton Durant 1905-1977. Trans Assoc Am Physicians (1978) 0.75
Thrombosis. Circulation (1969) 0.75
Thrombolytic therapy in surgical patients. Curr Surg (1981) 0.75
Revisiting the development of thrombolytic therapy: an historical perspective. Trans Stud Coll Physicians Phila (1989) 0.75
Creation of the recombinant tissue plasminogen activator (rt-PA) image and its influence on practice habits. J Am Coll Cardiol (1991) 0.75
Interrelationships between platelets and coagulation in the pathogenesis of venous thrombosis. S Afr Med J (1976) 0.75
Thrombolytic therapy for acute myocardial infarction. Am Heart J (1972) 0.75
[The Anturan reinfarct study]. Wien Med Wochenschr Suppl (1980) 0.75
The relationship of platelet coagulant activities to venous thrombosis following hip surgery. Br J Haematol (1976) 0.75
Preventing pulmonary embolism with heparin in low doses. Postgrad Med (1976) 0.75
Thrombolytic agents for acute evolving myocardial infarction: comparative effects. Ration Drug Ther (1987) 0.75
The venous system and the lung. Heart Lung (1978) 0.75
Role of platelet-active drugs in coronary artery disease. Cardiovasc Clin (1983) 0.75
Anticoagulant therapy: questions and answers. Compr Ther (1976) 0.75
Thrombolysis by urokinase. J Atheroscler Res (1969) 0.75
Current concepts of the relationship of thrombosis and thrombolysis. Res Publ Assoc Res Nerv Ment Dis (1966) 0.75
Drug trials in myocardial infarction. Lessons to be learned from the Anturane Reinfarction Trial. Eur J Clin Pharmacol (1980) 0.75
Urokinase. Ann Intern Med (1968) 0.75
Urokinase in thromboembolic disease: Pulmonary embolism. Am Heart J (1975) 0.75
[Sulfinpyrazone in the prevention of sudden death after myocardial infarction (author's transl)]. MMW Munch Med Wochenschr (1980) 0.75
The fibrinolytic system and its pharmacologic activation for thrombolysis. Cardiol Clin (1987) 0.75
Altered coagulability in tumor patients: introduction. Ann N Y Acad Sci (1974) 0.75
Report of the subcommittee on fibrinolysis and thrombolysis. Thromb Diath Haemorrh Suppl (1968) 0.75
Perspectives: fibrinolysis and thrombolysis. Thromb Diath Haemorrh Suppl (1966) 0.75
The rt-PA versus streptokinase controversy--III. J Am Coll Cardiol (1992) 0.75
Treatment of pulmonary embolism with urokinase. Results of clinical trial (phase 1). Circulation (1970) 0.75
Fibrinolytic agents. Dis Mon (1969) 0.75
Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes. Adv Prostaglandin Thromboxane Leukot Res (1982) 0.75
A tribute to Kenneth M. Brinkhous, M.D. Thromb Haemost (1979) 0.75
Thrombolytic agents. Annu Rev Pharmacol (1966) 0.75
Low-dose heparin for the prophylaxis of pulmonary embolism. Am Rev Respir Dis (1976) 0.75
Prospects in antithrombotic therapy. Am J Cardiol (1972) 0.75
Streptokinase. N Engl J Med (1969) 0.75
Observations on the plasma kallikreinogen (prekallikrein)-kallikrein enzyme system. Trans Assoc Am Physicians (1968) 0.75